Cartesian Therapeutics to Join H.C. Wainwright BioConnect Conference at NASDAQ

GAITHERSBURG, Md., May 13, 2024 – Cartesian Therapeutics, Inc. (NASDAQ:RNAC), a clinical-stage biotechnology firm at the forefront of mRNA cell therapy for autoimmune diseases, has announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. This event is scheduled for Monday, May 20, 2024, at 3:00 p.m. ET, where the Company's management will engage in a fireside chat. The event will be broadcasted live and accessible through the Events section on the Company's official website. A replay of the chat will be available for a limited duration.

Cartesian Therapeutics specializes in developing innovative mRNA cell therapies targeting autoimmune diseases. The Company's flagship product, Descartes-08, is an mRNA CAR-T therapy currently in Phase 2b clinical trials aimed at treating generalized myasthenia gravis. The product represents a potential first-in-class treatment option for this condition. Beyond this, Cartesian is planning further Phase 2 studies for systemic lupus erythematosus under an approved Investigational New Drug (IND) application, along with broader trials addressing additional autoimmune diseases.

The company's clinical pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T therapy. This further exemplifies the company's commitment to advancing treatment options for complex autoimmune conditions through cutting-edge science and innovation.

Cartesian Therapeutics is leveraging mRNA technology to pioneer new therapeutic pathways, aiming to drastically improve the lives of patients suffering from debilitating autoimmune diseases. The comprehensive clinical activities of Cartesian underscore its role as a leader in the biotech industry, focusing on transformative medical solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!